Differentiated medicines,
discovered at record pace

With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have discovered differentiated therapies for some of the most challenging and pervasive diseases — at record pace.

We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started.

Many Enveda molecules have
already advanced into R&D.
Watch their progress.

10 Development Candidates
01 Clinical Programs

ENV-294

Mechanism: Novel (Non-Kinase)

Indication: Atopic Dermatitis +

Phase 1

ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.

ESN-X

Mechanism: NLRP3/TL1A Pathway+ Inhibitor

Indication: Inflammatory Bowel Disease

IND enabling

ESN-X is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.

ESN-C

Mechanism: MRPGRX4 Antagonist

Indication: Cholestatic Pruritus

IND enabling

ESN-C is a potential first-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.

ESN-O

Mechanism: Novel (Hormone Mimetic)

Indication: Obesity

IND enabling

ESN-O is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ESN-O shows highly encouraging safety and tolerability for long-term use. ESN-O is expected to be in Phase 1 trials in 2025.

ESN-X1

Mechanism: NLRP3/TL1A Pathway+ Inhibitor

Indication: Multiple Liver

DC declared

ESN-X1 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ESN-X1 has reached DC and is ready for IND-enabling studies.

ESN-A

Mechanism: Novel

Indication: Idiopathic Pulmonary Fibrosis

DC declared

ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A has reached DC and is ready for IND-enabling studies.

ESN-X2

Mechanism: NLRP3/TL1A Pathway+ Inhibitor

Indication: Multiple Neurological, Obesity

DC declared

ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neurological and cardiometabolic disorders. ESN-X2 has reached DC and is ready for IND-enabling studies.

ESN-D

Mechanism: TGR5 Agonist

Indication: Inflammatory Bowel Disease

DC declared

ESN-D is a potential best-in-class, gut-preferred, oral TGR5 agonist being studied in inflammatory bowel disease. ESN-D has reached DC and is ready for IND-enabling studies.

ESN-Y

Mechanism: TGFβ Inhibitor

Indication: Fibrostenotic Crohn's

DC declared

ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.

ESN-Y1

Mechanism: TGFβ Inhibitor

Indication: Derm Fibrosis

DC declared

ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions.

ESN-Y2

Mechanism: TGFβ Inhibitor

Indication: Lung Fibrosis

Optimization Complete

ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is expected to be a DC by end of 2024.

ESN-N

Mechanism: NRF2 Agonist

Indication: Undisclosed

Optimization Complete

ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-Y2 is expected to be a DC by end of 2024.

ESN-G

Mechanism: MRGPRX2 Antagonist

Indication: Multiple Inflammatory

Optimization

ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G is expected to be a DC in early 2025.

ESN-B/B1

Mechanism: Novel

Indication: Chronic Pain

Optimization

ESN-B/B1 are first-in-class, oral small molecules being studied in multiple chronic pain conditions. ESN-B/B1 are expected to be DCs in 2025.

ESN-T

Mechanism: TL1A Antagonist

Indication: Multiple Inflammatory

Optimization

ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2025.

ESN-F

Mechanism: IL-4/13 Antagonist

Indication: Multiple Inflammatory

Optimization

ESN-F is a potential best-in-class, oral small molecule inhibitor of IL-4/13 for the treatment of multiple inflammatory diseases. Multiple promising scaffolds are in optimization with a DC expected in 2025.

Asset Name
Mechanism
Indication
Discovery
Optimization
IND-Enabling
Phase 1
Proof of Concept
ENV-294
Novel (Non-Kinase)
Atopic Dermatitis +
 
 
 

ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.

ESN-X
NLRP3/TL1A Pathway+ Inhibitor
Inflammatory Bowel Disease
 
 
 

ESN-X is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.

ESN-C
MRPGRX4 Antagonist
Cholestatic Pruritus
 
 
 

ESN-C is a potential first-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.

ESN-O
Novel (Hormone Mimetic)
Obesity
 
 
 

ESN-O is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ESN-O shows highly encouraging safety and tolerability for long-term use. ESN-O is expected to be in Phase 1 trials in 2025.

ESN-X1
NLRP3/TL1A Pathway+ Inhibitor
Multiple Liver
 
 
 

ESN-X1 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ESN-X1 has reached DC and is ready for IND-enabling studies.

ESN-A
Novel
Idiopathic Pulmonary Fibrosis
 
 
 

ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A has reached DC and is ready for IND-enabling studies.

ESN-X2
NLRP3/TL1A Pathway+ Inhibitor
Multiple Neurological, Obesity
 
 
 

ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neurological and cardiometabolic disorders. ESN-X2 has reached DC and is ready for IND-enabling studies.

ESN-D
TGR5 Agonist
Inflammatory Bowel Disease
 
 
 

ESN-D is a potential best-in-class, gut-preferred, oral TGR5 agonist being studied in inflammatory bowel disease. ESN-D has reached DC and is ready for IND-enabling studies.

ESN-Y
TGFβ Inhibitor
Fibrostenotic Crohn's
 
 
 

ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.

ESN-Y1
TGFβ Inhibitor
Derm Fibrosis
 
 
 

ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions.

ESN-Y2
TGFβ Inhibitor
Lung Fibrosis
 
 
 

ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is expected to be a DC by end of 2024.

ESN-N
NRF2 Agonist
Undisclosed
 
 
 

ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-Y2 is expected to be a DC by end of 2024.

ESN-G
MRGPRX2 Antagonist
Multiple Inflammatory
 
 
 

ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G is expected to be a DC in early 2025.

ESN-B/B1
Novel
Chronic Pain
 
 
 

ESN-B/B1 are first-in-class, oral small molecules being studied in multiple chronic pain conditions. ESN-B/B1 are expected to be DCs in 2025.

ESN-T
TL1A Antagonist
Multiple Inflammatory
 
 
 

ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2025.

ESN-F
IL-4/13 Antagonist
Multiple Inflammatory
 
 
 

ESN-F is a potential best-in-class, oral small molecule inhibitor of IL-4/13 for the treatment of multiple inflammatory diseases. Multiple promising scaffolds are in optimization with a DC expected in 2025.

  Development Candidate Declared

Be a part of our progress

Today’s mission: drug discovery.
Tomorrow’s possibilities: agriculture, nutrition, manufacturing, and more.

Together, we can rapidly multiply humanity’s knowledge of the natural
world’s chemistry and solve many of the greatest challenges in human
and planetary health. We’d love your support.

Partner With Us     Join The Team

Locations

Enveda
5700 Flatiron Parkway
Boulder, CO 80301

M/s Enveda Therapeutics India Pvt Ltd
3rd Floor, Building 3600 - Synergy Square-3,
Genome Valley, Hyderabad – 500101 India

Learning
from Life.
Copyright ©2024 ENVEDA All rights reserved